The reputation of congenital vascular malformation (CVM), a once-condemned disease among surgeons in the USA, has come a long way. ' Because of ill-planned approaches and limited knowledge, disastrous outcomes were often quite inevitable in the past.
Unfair condemnation 1 kept most surgeons, the sole challengers of CVM, in a severely restricted and conservative attitude for many decades while patients suffered the most.
But during the last two decades a new concept emerged, based on a multidisciplinary team approach.f which challenged this ever confusing problem quite successfully. CVM is no longer an enigma in modern medicine.
A new classification of CVM 3 helped to clear confusion arising from a reliance mostly on namebased nosology, and advanced technology opened a new chapter for diagnosis and subsequent treatment strategy. Based on this new information, approaches that combined traditional open surgery and a newly adopted embolosclerotherapy as endovascular surgery can now safely deliver long-term success in controlling CVMs with minimal morbidity and recurrence.
Embolosclerotherapy is now the treatment of choice for 'surgically inaccessible' lesions while open/excisional surgery is limited only to 'surgically accessible' lesions. Embolosclerotherapy further improves surgical outcomes when used as a perioperative supplemental therapy with minimum surgical m o r b i d i t y . 4 , After all, while surgery alone provides the chance of 'cure', endovascular surgery can provide an equivalent outcome with less risk, although it can only control the lesion.
In this issue, we present various issues regarding venous malformation (VM) since VM, as the most common CVM, is the lesion phlebologists are most likely to encounter.
We certainly hope this issue will give guidelines and motivation for your further exploration of other CVMs as well.
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